Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) will announce third quarter 2025 financial results and host a conference call and live audio webcast on Tuesday, November 4, 2025 at 8:30 a.m. ET.

Phone participants must register online to receive a dial-in number and personal PIN; web participants can register at ir.amicusrx.com (recommended 15 minutes before the call). An archived webcast and slides will be posted on the company website shortly after the live event.

Investor and media contacts are listed for follow-up.

PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025.

Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

An archived webcast and accompanying slides will be available on the Company's website shortly after the conclusion of the live event.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Brendan McEvoy
Executive Director, External Communications
bmcevoy@amicusrx.com
(609) 662-5005

FOLD–G

FAQ

When will Amicus Therapeutics (FOLD) report Q3 2025 results?

Amicus will report Q3 2025 results on November 4, 2025 during a scheduled call at 8:30 a.m. ET.

How do I join the Amicus (FOLD) Q3 2025 earnings call by phone?

Register using the online form to receive a dial-in number and personal PIN for phone access.

Where can I listen to the Amicus (FOLD) live audio webcast for Q3 2025?

Listen via the Investors section at ir.amicusrx.com; web registration 15 minutes before the call is recommended.

Will Amicus (FOLD) provide slides or an archived webcast after the Q3 2025 call?

Yes. An archived webcast and accompanying slides will be available on the company website shortly after the live event.

Who should investors contact for questions about Amicus (FOLD) Q3 2025 results?

Contact Andrew Faughnan, Vice President Investor Relations, at afaughnan@amicusrx.com or (609) 662-3809.

Will media have a separate contact for Amicus (FOLD) Q3 2025 communications?

Yes. Media can contact Brendan McEvoy, Executive Director External Communications, at bmcevoy@amicusrx.com or (609) 662-5005.